Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-κB expressions

BACKGROUND/AIM: Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage i...

Descripción completa

Detalles Bibliográficos
Autores principales: OLTULU, Fatih, BUHUR, Aylin, GÜREL, Çevik, KUŞÇU, Gökçe Ceren, DAĞDEVİREN, Melih, KARABAY YAVAŞOĞLU, Nefise Ülkü, KÖSE, Timur, YAVAŞOĞLU, Altuğ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific and Technological Research Council of Turkey 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018237/
https://www.ncbi.nlm.nih.gov/pubmed/31652041
http://dx.doi.org/10.3906/sag-1901-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018237/
https://www.ncbi.nlm.nih.gov/pubmed/31652041
http://dx.doi.org/10.3906/sag-1901-15

Ejemplares similares